Adnexus outlines $86M IPO to advance adnectins

With its lead therapy poised to begin mid-stage trials early next year, Adnexus Therapeutics has filed papers with the SEC for an IPO designed to raise $86.3 million. The company is developing adnectins, which relies on a protein engineering system. Angiocept, its lead adnectin, has been in an early stage study to prevent the formation of blood vessels in tumors. And most of the money is hopes to raise on the market would fund that trial and other pipeline studies. Adnexus--which is in a partnership with Bristol-Myers Squibb, says that it lost $11.9 million in the first half of this year.

- see the release form Adnexus
- check out the AP report for more info

Related Article:
Adnexus raises $15.5M. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.